Demonstrated reduction in ARR |
Demonstrated reduction in 3-month EDSS progression |
Demonstrated reduction in brain lesions |
||
|
See how MAVENCLAD |
See how MAVENCLAD delivered a 33% |
Discover how MAVENCLAD demonstrated an 86% relative reduction in T1 Gd+ lesions and 73% in T2 lesions over 96 weeks vs. placebo (p<0.001; mean lesions: T1 Gd+, 0.12 vs. 0.91; T2, 0.38 vs. 1.43; secondary endpoint). |
Measuring efficacy – the CLARITY study
CLARITY study design1


Reference
92% of MAVENCLAD patients (vs. 87% of the placebo group) completed the full 96-week study. 3.5% of MAVENCLAD patients discontinued the study due to AEs.1,2
Reference
§ The 5.25 mg/kg dosage regimen is not available.
¶ Combined unique lesions were defined as new GD+ T1-weighted lesions or new nonenhancing or enlarging T2-weighted lesions (without double-counting).